97. Ulcerative colitis Clinical trials / Disease details
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00309660 (ClinicalTrials.gov) | November 2005 | 30/3/2006 | Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis | Ulcerative Colitis | Drug: Rosiglitazone | Herlev Hospital | NULL | Recruiting | 18 Years | 80 Years | Both | 20 | Phase 1/Phase 2 | Denmark | |
| 2 | NCT00065065 (ClinicalTrials.gov) | September 2002 | 16/7/2003 | A Trial of Rosiglitazone for Ulcerative Colitis | A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis | Ulcerative Colitis;Inflammatory Bowel Disease | Drug: Rosiglitazone;Drug: Placebo | James Lewis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);GlaxoSmithKline | Completed | 18 Years | N/A | All | 105 | Phase 2 | United States |